MKI67 and neoplasm: Beyond PD-L1, the Chinese Society of Clinical Oncology (CSCO) guidelines and the World Health Organization (WHO) classification also recommend reporting on Ki-67 and tumor-infiltrating lymphocytes (TILs) as additional markers to better determine the molecular characteristics of the tumor.